OverviewSuggest Edit

Adagene is an antibody discovery and development biotechnology company specializing in oncology immunotherapy. It is creating a pipeline of mono-specific and bi-specific antibody therapeutics with the help of computational biology and artificial intelligence.

TypePublic
Founded2012
HQSuzhou, CN
Websiteadagene.com

Latest Updates

Employees (est.) (Dec 2020)198
Revenue (FY, 2019)$480 K(-68%)
Share Price (May 2021)$14.5
Cybersecurity ratingAMore

Key People/Management at Adagene

Man Kin Tam

Man Kin Tam

Chief Financial Officer
Felix Du

Felix Du

Chief Technology Officer
Peter Luo

Peter Luo

Chairman of the Board of Directors
Hua Gong

Hua Gong

Chief Operating Officer and Head of Precision Medicine
Jc Xu

Jc Xu

Chief Scientific Officer
Qinghai Zhao

Qinghai Zhao

Chief Manufacturing Officer
Show more

Adagene Office Locations

Adagene has offices in Suzhou, San Diego and San Francisco
Suzhou, CN (HQ)
4f, building c14, no, 218 Xinghu St, Wuzhong Qu
San Diego, CA, US
10179 Huennekens St
San Francisco, CA, US
315 Montgomery St, San Francisco
Show all (3)

Adagene Financials and Metrics

Adagene Revenue

Adagene's revenue was reported to be $480 k in FY, 2019 which is a 68.2% decrease from the previous period.
USD

Revenue (FY, 2019)

480.0k

Revenue growth (FY, 2018 - FY, 2019), %

(68.2%)

Net income (FY, 2019)

(16.4m)

EBIT (FY, 2019)

(19.2m)

Market capitalization (3-May-2021)

639.7m

Closing stock price (3-May-2021)

14.5

Cash (30-Sept-2020)

82.9m

EV

563.1m
Adagene's current market capitalization is $639.7 m.
USDFY, 2018FY, 2019

Revenue

1.5m480.0k

Revenue growth, %

(68%)

General and administrative expense

2.8m3.4m

R&D expense

16.1m16.2m
Annual
USDFY, 2018FY, 2019

Cash

16.1m92.5m

Accounts Receivable

480.0k

Prepaid Expenses

295.5k211.4k

Current Assets

51.8m103.9m
Quarterly
USDQ3, 2020

Cash

82.9m

Prepaid Expenses

1.4m

Current Assets

86.6m

PP&E

1.8m
Annual
USDFY, 2018FY, 2019

Net Income

(15.3m)(16.4m)

Depreciation and Amortization

909.0k816.7k

Accounts Payable

389.1k153.7k

Cash From Operating Activities

(14.3m)(18.2m)
Quarterly
USDQ3, 2019Q3, 2020

Net Income

(11.8m)(29.6m)

Depreciation and Amortization

602.7k647.2k

Accounts Payable

(70.7k)494.6k

Cash From Operating Activities

(11.8m)(20.0m)
USDFY, 2018

Debt/Equity

-0.1 x

Financial Leverage

-1.3 x
Show all financial metrics

Adagene Operating Metrics

Q3, 2020

IND-Enabling Stage Products

6

Phase I Trials Products

4
Show all operating metrics

Adagene Acquisitions / Subsidiaries

Company NameDateDeal Size
ADAGENE AG
ADAGENE AUSTRALIA PTY LTD
Adagene (Hong Kong) Limited
Adagene Incorporated
ADAGENE PTE. LTD.
Adagene (Suzhou) Limited

Adagene Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Adagene Online and Social Media Presence

Embed Graph

Adagene News and Updates

Adagene Presents Preclinical Data from Lead SAFEbody™ Program, ADG126, at the American Association for Cancer Research (AACR) Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, April 13, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced updated preclini…

Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates

- Successfully completed Initial Public Offering raising approximately US$161 million in gross proceeds--Reported clinical data for anti-CD137 and two anti-CTLA-4 programs--Advanced five discovery programs into IND-enabling stage--Established multiple academic and industry partnerships--Further stre…

Adagene Announces Clinical Advancement for ADG116

-NEObody™ product candidate ADG116 has been well tolerated in ongoing Phase 1 clinical trial- -Promising pharmacodynamic biomarker signals demonstrate clinical proof of mechanism--Poised for global expansion-

Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program

SAFEbody technology enables precision masking of antibodies for enhanced safety SAFEbody technology enables precision masking of antibodies for enhanced safety

Adagene Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option

SAN FRANCISCO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies, today announced the closing…

Adagene Inc. Announces Pricing of Initial Public Offering

SAN FRANCISCO, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies, today announced tha…
Show more

Adagene Frequently Asked Questions

  • When was Adagene founded?

    Adagene was founded in 2012.

  • Who are Adagene key executives?

    Adagene's key executives are Man Kin Tam, Felix Du and Peter Luo.

  • How many employees does Adagene have?

    Adagene has 198 employees.

  • What is Adagene revenue?

    Latest Adagene annual revenue is $480 k.

  • What is Adagene revenue per employee?

    Latest Adagene revenue per employee is $2.4 k.

  • Who are Adagene competitors?

    Competitors of Adagene include Anavex, Shanghai Henlius Biotech and UT Health San Antonio MD Anderson Cancer Center.

  • Where is Adagene headquarters?

    Adagene headquarters is located at 4f, building c14, no, 218 Xinghu St, Wuzhong Qu, Suzhou.

  • Where are Adagene offices?

    Adagene has offices in Suzhou, San Diego and San Francisco.

  • How many offices does Adagene have?

    Adagene has 3 offices.